Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Andrés Gomez-de-León, David Gómez-Almaguer, Guillermo J. Ruiz-Delgado & Guillermo J. Ruiz-Arguelles. (2017) Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Expert Review of Hematology 10:9, pages 809-819.
Read now
Read now
Vikram Mathews. (2014) Generic imatinib: the real-deal or just a deal?. Leukemia & Lymphoma 55:12, pages 2678-2680.
Read now
Read now
Teoman Soysal, Ahmet Emre Eskazan & Muhlis Cem Ar. (2014) Generics in chronic myeloid leukemia: current arguments for and against and the established evidence. Expert Review of Hematology 7:6, pages 697-699.
Read now
Read now
Articles from other publishers (13)
Deepak Goni, Arihant Jain, Charanpreet Singh, Nishant Jindal, Ram Nampoothiri, Aditya Jandial, Deepesh Lad, Alka Khadwal, Gaurav Prakash, Shano Naseem, Neelam Varma & Pankaj Malhotra. (2023) Feasibility of treatment-free remission with generic imatinib. Indian Journal of Medical Research 157:1, pages 87-91.
Crossref
Crossref
Katia B. Pagnano, Ana Ines Varela, Carolina Pavlovsky, Israel Bendit, Vaneuza A. M. Funke & Virginia Abello Polo. (2021) Challenges in Chronic Myeloid Leukemia Management in South America. Current Hematologic Malignancy Reports 16:5, pages 440-447.
Crossref
Crossref
Abdülkadir Erçalışkan, Duygu Seyhan Erdoğan & Ahmet Emre Eşkazan. (2021) Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Advances 5:17, pages 3344-3353.
Crossref
Crossref
Maria Gemelli, Elena Maria Elli, Chiara Elena, Alessandra Iurlo, Tamara Intermesoli, Margherita Maffioli, Ester Pungolino, Maria Cristina Carraro, Mariella D'Adda, Francesca Lunghi, Michela Anghileri, Nicola Polverelli, Marianna Rossi, Mattia Bacciocchi, Elisa Bono, Cristina Bucelli, Francesco Passamonti, Laura Antolini & Carlo Gambacorti-Passerini. (2020) Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. BLOOD RESEARCH 55:3, pages 139-145.
Crossref
Crossref
Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang & Qian Jiang. (2020) Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center. Clinical Lymphoma Myeloma and Leukemia 20:6, pages e304-e315.
Crossref
Crossref
Iman Abou Dalle, Hagop Kantarjian, Jan Burger, Zeev Estrov, Maro Ohanian, Srdan Verstovsek, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia‐Manero, Elias Jabbour & Jorge Cortes. (2019) Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Medicine 8:15, pages 6559-6565.
Crossref
Crossref
Irena Ćojbašić, Lana Mačukanović-Golubović, Miodrag Vučić & Žarko Ćojbašić. (2019) Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up. Clinical Lymphoma Myeloma and Leukemia 19:9, pages e526-e531.
Crossref
Crossref
Massimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, Maria Cristina Miggiano, Marco Danini, Claudia Minotto, Davide Griguolo, Luciana Marin, Luca Frison, Fabio D’Amore, Marco Basso, Roberto Sartori, Martina Tinelli, Manuela Stulle, Stefania Fortuna, Angela Bonalumi, Giovanni Bertoldero, Ercole De Biasi, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Giovanni Pizzolo, Mauro Krampera & Mario Tiribelli. (2018) Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. Leukemia Research 74, pages 75-79.
Crossref
Crossref
Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek & Teoman Soysal. (2017) Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 804-811.
Crossref
Crossref
Tomasz Sacha, Joanna G?ra-Tybor, Monika Szarejko, Gra?yna Bober, Olga Grzybowska-Izydorczyk, Joanna Niesiob?dzka-Kr??el, Marek Dudzi?ski, Ewa Wasilewska, Krzysztof My?liwiec, Justyna Gil, Micha? Gniot, Iwona Pietkun, Ewa M?dra?, Jadwiga Ho?ojda, Joanna W?c?aw & Krzysztof Giannopoulos. (2017) A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry. American Journal of Hematology 92:7, pages E125-E128.
Crossref
Crossref
Y Tony Yang, Sumimasa Nagai, Brian K Chen, Zaina P Qureshi, Akida A Lebby, Samuel Kessler, Peter Georgantopoulos, Dennis W Raisch, Oliver Sartor, Terhi Hermanson, Robert C Kane, William J Hrushesky, Joshua J Riente, LeAnn B Norris, Laura R Bobolts, James O Armitage & Charles L Bennett. (2016) Generic oncology drugs: are they all safe?. The Lancet Oncology 17:11, pages e493-e501.
Crossref
Crossref
Ahmet Emre Eskazan & Teoman Soysal. (2015) Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpaşa experience. Journal of Oncology Pharmacy Practice 22:2, pages 382-384.
Crossref
Crossref
. (2016) Imatinib. Reactions Weekly 1583:1, pages 593-593.
Crossref
Crossref